Document is current
Any future updates will be listed below
-
Authors
Heugenhauser, Johanna
Visus, Carmen
Buchroithner, Johanna
Marosi, Christine
Rössler, Karl
Felzmann, Thomas
Widhalm, Georg
Iglseder, Sarah
Nowosielski, Martha
Erhart, Friedrich
-
Funding
Funding for this research was provided by:
Medical Scientific Fund of the Mayor of the City of Vienna (19071)
“Herbert Tumpel Preis” 2021
City of Vienna Fund for Innovative Cancer Research (23016)
- License Information
-
More Information
Article History
Received: 22 September 2025
Accepted: 4 April 2026
First Online: 28 April 2026
Declarations
:
: This retrospective analysis includes participants from a national, randomized, multicenter, open-label phase II trial evaluating a dendritic-cell vaccine (Audencel) for newly diagnosed WHO grade 4 glioblastoma (EudraCT 2009-015979-27) [29]. All individuals provided written informed consent prior to enrolment. The study protocol had been approved by the local institutional ethics committee (approval number TRX 2/P-II-018).
: Not applicable.
: GW is on the advisory board of Servier. The other authors declare that they have no competing interests.
